CRL
Charles River Laboratories
Charles River Laboratories historical holders
total: 7
Jensen Investment Management Charles River Laboratories transactions over time
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 4
- Held since:
- 2022 Q2
- Held for:
- 10 quarters
- Latest activity:
- 2024 Q4
Eric H. Schoenstein has been an institutional investor in Charles River Laboratories (CRL) since 2022 Q2. According to 2026 Q1 report, Eric H. Schoenstein doesn't hold any shares. The fund/company first acquired CRL in 2022 Q2, initially purchasing 8,660 shares. Since the initial investment, Jensen Investment Management has made 9 more transactions in this position.
When did Eric H. Schoenstein exit their CRL position?
Eric H. Schoenstein no longer holds Charles River Laboratories (CRL). They sold off their entire position in 2024 Q4, closing out an investment that began in 2022 Q2.
When did Eric H. Schoenstein first invest in CRL?
Eric H. Schoenstein first invested in Charles River Laboratories (CRL) in 2022 Q2 at the reported quarter-end price of $213.97 per share, acquiring 8,660 shares in their initial purchase.
What is Eric H. Schoenstein's average cost basis for CRL?
Based on historical transaction data, Eric H. Schoenstein's estimated cost basis for Charles River Laboratories (CRL) is approximately $207.13 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $207.12
- Weighted AVG sell price:
- $205.41
CRL transactions history by Jensen Investment Management
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.00%
|
0
|
$196.97
|
|
-100% (-12,180)
|
-0.02%
|
|
2024 Q3
|
0.02%
|
12,180
|
$196.97
|
$2,399,095
|
-23.44% (-3,730)
|
-0.01%
|
|
2024 Q2
|
0.03%
|
15,910
|
$206.58
|
$3,286,688
|
-32.81% (-7,770)
|
-0.01%
|
|
2024 Q1
|
0.05%
|
23,680
|
$270.95
|
$6,416,096
|
-7.25% (-1,850)
|
-0%
|
|
2023 Q3
|
0.04%
|
25,530
|
$195.98
|
$5,003,369
|
+2.20% (+550)
|
+0%
|
|
2023 Q2
|
0.04%
|
24,980
|
$210.25
|
$5,252,045
|
-3.10% (-800)
|
-0%
|
|
2023 Q1
|
0.04%
|
25,780
|
$198.03
|
$5,105,213
|
+11.70% (+2,700)
|
+0%
|
|
2022 Q4
|
0.04%
|
23,080
|
$217.90
|
$5,029,132
|
+32.87% (+5,710)
|
+0.01%
|
|
2022 Q3
|
0.03%
|
17,370
|
$196.78
|
$3,418,000
|
+100.58% (+8,710)
|
+0.01%
|
|
2022 Q2
|
0.02%
|
8,660
|
$213.97
|
$1,853,000
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.